Sorafenib does not improve efficacy of chemotherapy in advanced pancreatic cancer: A GISCAD randomized phase II study
Stefano Cascinu(Vita-Salute San Raffaele University), Michela Cinquini(Mario Negri Institute for Pharmacological Research), Rossana Berardi(Marche Polytechnic University), Francesco Di Costanzo, Salvatore Siena(University of Milan), Vittorina Zagonel(Istituto Oncologico Veneto), PierFranco Conte(University of Padua), Stefania Mosconi(Ospedale Papa Giovanni XXIII), C. Boni(Ospedale Santa Maria), Federica Villa(Aziende Socio Sanitarie Territoriali di Lecco), Giuseppe Tonini(Campus Bio Medico University Hospital), Sandro Barni, Roberto Labianca(Ospedale Papa Giovanni XXIII), Daris Ferrari, Paolo Bidoli(Fondazione IRCCS Istituto Nazionale dei Tumori), Alberto F. Sobrero(Ospedale Policlinico San Martino), Francesco Caprioni(Ospedale Policlinico San Martino), Enrico Aitini, Luca Faloppi(University of Macerata)
Cited by 52
Related Papers
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
|Science Translational Medicine|2014|5.1k
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
|Journal of Clinical Oncology|2000|3.8k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
|Journal of Clinical Oncology|2000|2.3k
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.
|IRIS UNIMORE (University of Modena and Reggio Emilia)|2005|1.6k